Dong-Ku Kang,
Assistant Research Scientist,
University of California-Irvine
Dr. Dong-Ku Kang is a Research Scientist of Biomedical engineering at University of California Irvine and he was a Newton Research Fellow at Imperial College London before joining UC-Irvine. Dr. Kang is also the Co-founder of Velox Biosystems, a start-up company that aims to develop rapid and sensitive diagnostic technologies. He has co-authored > 40 journal articles in highly respected journals including Nature Communications, Chemical Communications, Analytical Chemistry and Lab On A Chip. Dr. Kang has received numerous awards including the prestigious Newton Research Award (2009, the world’s top 50 young investigators, Royal Society, UK) and Tony B. Academic Award (SLAS, USA). His current research aim is the development of miniaturized devices for diagnosis and monitoring of various diseases including cancer, neurological disorder, and infectious diseases. More specifically, his research is dedicated to develop single molecule (or cell) digital detection for the absolute quantification of rare biomarkers in the complex biological samples such as blood and plasma using nano/micro technologies.
Rapid and Absolute Quantification of Rare Antibiotic-resistant Bacteria Using Droplet-based Microfluidics
Monday, 28 September 2015 at 15:30
Add to Calendar ▼2015-09-28 15:30:002015-09-28 16:30:00Europe/LondonRapid and Absolute Quantification of Rare Antibiotic-resistant Bacteria Using Droplet-based MicrofluidicsPoint-of-Care Diagnostics and Global Health World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Antimicrobial resistance is a growing health problem in the United States and worldwide. According to the Centers for Disease Control and Prevention (CDC), more than two million people are infected annually with antibiotic-resistant infections, with >23,000 deaths. Especially, extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae is commonly found in K. pneumoniae and Escherichia coli are among the most prevalent antimicrobial resistant pathogens. Rapid diagnostics are particularly needed for pathogens such as E. coli, which are common, virulent, and have acquired ESBLs. Furthermore, diagnostic tests that can confirm the presence of ESBLs regardless of the species would be exceedingly valuable in directing early therapy and enabling better antimicrobial stewardship for those not infected with antibiotic resistant pathogens. Unfortunately, existing bacterial detection methods are limited in their inability to rapidly detect and identify pathogens that typically occur at low concentrations in blood (1 to 100 colony-forming unit (CFU)/mL) as is commonly found in adult BSIs. Here, we will discuss about our strategy for monitoring beta-lactamase producing bacteria at single-cell sensitivity within a few hours by miniaturized droplet-based microfluidic system.
Add to Calendar ▼2015-09-28 00:00:002015-09-30 00:00:00Europe/LondonPoint-of-Care Diagnostics and Global Health World CongressPoint-of-Care Diagnostics and Global Health World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-09-28 15:30:002015-09-28 16:30:00Europe/LondonRapid and Absolute Quantification of Rare Antibiotic-resistant Bacteria Using Droplet-based MicrofluidicsPoint-of-Care Diagnostics and Global Health World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
